Le Haillan, France – May 19, 2026 – Myonex announces the expansion of its primary packaging capabilities with the authorization of GMP (Good Manufacturing Practices) Primary Packaging of highly potent and hazardous drug products, including cytotoxic and hormonal compounds, at its Le Haillan facility, France.
As clinical pipelines and commercial portfolios evolve to include a broader range of chemotherapies, immunosuppressive, targeted and hormone-based therapies, there is a growing need for primary packaging capabilities adapted to stringent handling and containment requirements, while maintaining execution reliability and timeline integrity.
Backed by decades of experience in blistering and bottling of oral solid dose products, the Myonex Le Haillan site is now authorized for handling drugs with high exposure risk, with dedicated containment, enabling support for projects involving products with strict handling requirements.
This expansion triples Myonex’s highly potent and hazardous drug primary packaging capacity, strengthening its ability to secure packaging timelines and ensure continuity of supply for clients managing these types of products.
“In line with evolving needs across clinical and commercial markets, we have upgraded one of our primary packaging suites to meet GMP requirements for handling hazardous compounds. Regulatory authorizations have been granted, equipment qualification is complete, and the first blisters of highly potent drug products have been produced. We are ready to take on new products immediately.” said Louis Ducongé, Site Director, Myonex Le Haillan, France.
Across all primary packaging operations, Myonex maintains a consistent execution standard:
- No deprioritization: timelines remain protected
- Solutioning mindset: operations proactively align with study-specific constraints and protocol evolution, as well as commercial product requirements
- Proven reliability: studies remain on track, batch after batch
With this expansion, Myonex continues to align its capabilities with the evolving needs of biotech and pharmaceutical companies, including products with demanding handling and unique packaging requirements.
About Myonex
Myonex is an industry leader in global clinical trial supply and pharmaceutical commercial services. Our suite of integrable services and solutions helps pharmaceutical, biotech, and CRO partners advance medicine by reducing time, costs, and complexity. With locations in the US, Germany, UK, and France, our comprehensive, client-focused approach, coupled with expert project management, ensures seamless execution across regions, optimizes supply chain efficiency, and adapts to evolving trial or project needs while delivering quality, flexibility, and global scale. Learn more at www.myonex.com.